Targeted radiation delivered directly to brain tumor cavity in new trial
NCT ID NCT07648823
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a single dose of a radioactive drug called [177Lu]Lu-XT771 in people with recurrent glioblastoma, an aggressive brain cancer. The drug is injected directly into the cavity left after tumor removal surgery, aiming to deliver radiation precisely to cancer cells while sparing healthy tissue. The study involves only 3-5 participants and focuses on safety, how the drug spreads in the body, and its potential to slow tumor growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[177Lu]Lu-XT771 (a radioactive drug injected into the tumor cavity)
What this could lead to
If successful, this approach could provide a new, targeted treatment option for recurrent glioblastoma, potentially slowing tumor growth with fewer side effects than systemic therapies.
What could go wrong
This is a very early, small study (only 3-5 participants) designed primarily to test safety and dosing. The treatment may not shrink tumors or improve survival, and there are risks from radiation exposure to healthy brain tissue and other organs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tiantan Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100070, China
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact